Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel four‐gene signature predicts immunotherapy response of patients with different cancers

19 May 2022

Abstract excerpt

BACKGROUND: Immune checkpoint blockade (ICB) therapy has demonstrated favorable clinical efficacy, particularly for advanced or difficult-to-treat cancer types. However, this therapy is ineffective for many patients displaying lack of immune response or resistance to ICB. This study aimed to establish a novel four-gene signature (CD8A, CD8B, TCF7, and LEF1) to provide a prognostic immunotherapy biomarker for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35588138
DOI: 10.1002/jcla.24494

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel four‐gene signature predicts immunotherapy response of patients with different cancersPMID 35588138Read ↗

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read ↗

An Immune Gene Signature for Prediction of Overall Survival and Response to Immune Checkpoint Inhibitors Therapy in Patients with Lung AdenocarcinomaSemantic proximity Read ↗

An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinomaSemantic proximity Read ↗

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung AdenocarcinomaSemantic proximity Read ↗

Risk stratification based on immune signature and prediction of immune checkpoint inhibitor’s efficacy for bladder urothelial carcinomaSemantic proximity Read ↗

IRGS: an immune-related gene classifier for lung adenocarcinoma prognosisSemantic proximity Read ↗

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.Semantic proximity Read ↗

Prognostic implications of a four-gene signature in non-muscle invasive bladder cancerSemantic proximity Read ↗

An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle‐invasive bladder cancer (MIBC)Semantic proximity Read ↗

Construction of the Novel Immune Risk Scoring System Related to CD8 + T Cells in Uterine Corpus Endometrial CarcinomaSemantic proximity Read ↗

A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanomaSemantic proximity Read ↗

Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung AdenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.